Enanta Pharmaceuticals Inc’s filing revealed that its Chief Product Strategy Officer Kieffer Tara Lynn unloaded Company’s shares for reported $18401.0 on Dec 06 ’24. In the deal valued at $8.06 per share,2,283 shares were sold. As a result of this transaction, Kieffer Tara Lynn now holds 29,305 shares worth roughly $0.18 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Luu Brendan sold 2,283 shares, generating $18,401 in total proceeds. Upon selling the shares at $8.06, the Chief Business Officer now owns 36,047 shares.
Before that, Rottinghaus Scott T. sold 866 shares. Enanta Pharmaceuticals Inc shares valued at $6,980 were divested by the Chief Medical Officer at a price of $8.06 per share. As a result of the transaction, Rottinghaus Scott T. now holds 17,918 shares, worth roughly $0.11 million.
JP Morgan downgraded its Enanta Pharmaceuticals Inc [ENTA] rating to an Underweight from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who decreased its forecast for the stock in early August from “a Buy” to “a Hold”. H.C. Wainwright began covering ENTA with “Buy” recommendation on December 09, 2022. Evercore ISI revised its rating on July 06, 2022. It rated ENTA as “an Outperform” which previously was an “an In-line”.
Price Performance Review of ENTA
On Tuesday, Enanta Pharmaceuticals Inc [NASDAQ:ENTA] saw its stock fall -2.35% to $6.22. Over the last five days, the stock has lost -0.49%. Enanta Pharmaceuticals Inc shares have fallen nearly -35.18% since the year began. Nevertheless, the stocks have fallen -33.33% over the past one year. While a 52-week high of $17.80 was reached on 04/01/24, a 52-week low of $5.70 was recorded on 12/18/24. SMA at 50 days reached $9.58, while 200 days put it at $12.35.
Levels Of Support And Resistance For ENTA Stock
The 24-hour chart illustrates a support level at 5.82, which if violated will result in even more drops to 5.54. On the upside, there is a resistance level at 6.29. A further resistance level may holdings at 6.48. The Relative Strength Index (RSI) on the 14-day chart is 30.47, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.59, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 89.72%. Stochastics %K at 14.14% indicates the stock is a buying.
How much short interest is there in Enanta Pharmaceuticals Inc?
A steep rise in short interest was recorded in Enanta Pharmaceuticals Inc stocks on 2024-10-31, growing by 0.45 million shares to a total of 3.44 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 2.99 million shares. There was a rise of 13.21%, which implies that there is a positive sentiment for the stock.
